Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 5050-5061

  Barretto, Naina ^a,b,c   Sainz, Bruno ^b,d   Hussain, Snawar ^a,b   Uprichard, Susan L ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ABBVIE INC   (United States)

^d Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CARRIER PROTEINS AND BINDING PROTEINS; EZETIMIBE; FERRISTATIN; MICROSOMAL TRANSFER PROTEIN; NARINGENIN; NPC1L1 RECEPTOR; NSC 306711; RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CELL DIVISION; CELL SPREADING; CELLULAR SECRETION; CONTROLLED STUDY; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION;

CELL LINE; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS;

EID: 84897568257     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03241-13     Document Type: Article

References (64)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. 2011. Hepatitis C virus infection in U.S.A.: an estimate of true prevalence. Liver Int. 31: 1090-1101. http://dx.doi.org/10.1111/j.1478-3231.2011.02494.x.
3. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35-S46. http://dx.doi.org/10.1053/jhep.2002.36806.
4. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576. http://dx.doi.org/10.1053/j.gastro.2007.04.061.
5. O'Leary JG, Lepe R, Davis GL. 2008. Indications for liver transplantation. Gastroenterology 134:1764-1776. http://dx.doi.org/10.1053/j.gastro.2008.02.028.
6. Lange CM, Sarrazin C, Zeuzem S. 2010. Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol. Ther. 32:14-28. http://dx.doi.org/10.1111/j.1365-2036.2010.04317.x.
7. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462. http://dx.doi.org/10.1053/j.gastro.2009.11.055.
8. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:41003-41012. http://dx.doi.org/10.1074/jbc.M302267200.
9. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. 2002. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J. Med. Virol. 68:206-215. http://dx.doi.org/10.1002/jmv.10196.
10. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. 2003. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 100:4498-4503. http://dx.doi.org/10.1073/pnas.0831128100.
11. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R. 2003. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278:20358-20366. http://dx.doi.org/10.1074/jbc.M301284200.
12. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R. 1999. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57:223-229. http://dx.doi.org/10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4.
13. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. 1999. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 96:12766-12771. http://dx.doi.org/10.1073/pnas.96.22.12766.
14. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025. http://dx.doi.org/10.1093/emboj/cdf529.
15. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941. http://dx.doi.org/10.1126/science.282.5390.938.
16. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805.
17. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. http://dx.doi.org/10.1038/nature07684.
18. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. 2009. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83:2011-2014. http://dx.doi.org/10.1128/JVI.01888-08.
19. Sainz B, Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18:281-285. http://dx.doi.org/10.1038/nm.2581.
20. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. 2011. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85:596-605. http://dx.doi.org/10.1128/JVI.01592-10.
21. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH. 2009. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 90:48-58. http://dx.doi.org/10.1099/vir.0.006700-0.
22. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P, McKeating JA. 2008. HepatitisCvirus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17-24. http://dx.doi.org/10.1002/hep.21959.
23. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17:589-595. http://dx.doi.org/10.1038/nm.2341.
24. Martin DN, Uprichard SL. 2013. Identification of transferrin receptor 1 as a hepatitisCvirus entry factor. Proc. Natl. Acad. Sci. U. S. A. 110:10777-10782. http://dx.doi.org/10.1073/pnas.1301764110.
25. Weinglass AB, Kohler M, Schulte U, Liu J, Nketiah EO, Thomas A, Schmalhofer W, Williams B, Bildl W, McMasters DR, Dai K, Beers L, McCann ME, Kaczorowski GJ, Garcia ML. 2008. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. U. S. A. 105:11140-11145. http://dx.doi.org/10.1073/pnas.0800936105.
26. Chang TY, Chang C. 2008. Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metab. 7:469-471. http://dx.doi.org/10.1016/j.cmet.2008.05.001.
27. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 2008. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82:2120-2129. http://dx.doi.org/10.1128/JVI.02053-07.
28. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. 2008. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47: 1437-1445. http://dx.doi.org/10.1002/hep.22197.
29. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
30. Gastaminza P, Kapadia SB, Chisari FV. 2006. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol. 80:11074-11081. http://dx.doi.org/10.1128/JVI.01150-06.
31. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, McKeating JA, Chisari FV. 2006. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80:11082-11093. http://dx.doi.org/10.1128/JVI.01307-06.
32. Sainz B, Jr, Barretto N, Uprichard SL. 2009. Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. PLoS One 4:e6561. http://dx.doi.org/10.1371/journal.pone.0006561.
33. Yu X, Sainz B, Jr, Uprichard SL. 2009. Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrob. Agents Chemother. 53:4311-4319. http://dx.doi.org/10.1128/AAC.00495-09.
34. Sainz B, Jr, Chisari FV. 2006. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J. Virol. 80:10253-10257. http://dx.doi.org/10.1128/JVI.01059-06.
35. Choi S, Sainz B, Jr, Corcoran P, Uprichard S, Jeong H. 2009. Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 39:205-217. http://dx.doi.org/10.1080/00498250802613620.
36. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org/10.1053/j.gastro.2003.09.023.
37. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, Nagayama K, Tanaka T, Wakita T. 2001. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64:334-339. http://dx.doi.org/10.1002/jmv.1055.
38. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. http://dx.doi.org/10.1038/nm1268.
39. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377. http://dx.doi.org/10.1002/hep.22673.
40. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J. 2008. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. U. S. A. 105:997-1002. http://dx.doi.org/10.1073/pnas.0711044105.
41. Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J. 2008. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198:1756-1765. http://dx.doi.org/10.1086/593021.
42. Yu X, Uprichard SL. 2010. Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening. Curr. Protoc. Microbiol. Chapter 17:Unit 17.5. http://dx.doi.org/10.1002/9780471729259.mc1705s18.
43. Knipe D, Howley PM. 2007. Principles of virology, 5th ed, vol 1, p 30-43. Lippincott Williams & Wilkins, Philadelphia, PA.
44. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27. http://dx.doi.org/10.1038/nm1698.
45. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
46. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. 2009. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51:1144-1157. http://dx.doi.org/10.1002/hep.23445.
47. Komurian-Pradel F, Perret M, Deiman B, Sodoyer M, Lotteau V, Paranhos-Baccala G, Andre P. 2004. Strand specific quantitative realtime PCR to study replication of hepatitis C virus genome. J. Virol. Methods 116:103-106. http://dx.doi.org/10.1016/j.jviromet.2003.10.004.
48. Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, Yu X, Garry RF, Uprichard SL. 2010. The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology 407:110-119. http://dx.doi.org/10.1016/j.virol.2010.07.026.
49. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 104:5848-5853. http://dx.doi.org/10.1073/pnas.0700760104.
50. Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, Chung RT, Yarmush ML, Nahmias Y. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J. Hepatol 55:963-971. http://dx.doi.org/10.1016/j.jhep.2011.02.011.
51. Jiang J, Luo G. 2009. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J. Virol. 83:12680-12691. http://dx.doi.org/10.1128/JVI.01476-09.
52. Horonchik L, Wessling-Resnick M. 2008. The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem. Biol. 15:647-653. http://dx.doi.org/10.1016/j.chembiol.2008.05.011.
53. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. 2007. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 117:1968-1978. http://dx.doi.org/10.1172/JCI30060.
54. Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, Davis MA, Michaely P, Liu P, Willingham MC, Rudel LL. 2006. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem. 281:6616-6624. http://dx.doi.org/10.1074/jbc.M511123200.
55. Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51:43-53.
56. Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wolk B, Kaderali L, Pietschmann T. 2014. Apolipoprotein E co-determines tissue-tropism of hepatitis C virus and it is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J. Virol. 88:1433-1446. http://dx.doi.org/10.1128/JVI.01815-13.
57. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T. 2008. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J. Virol. 82:7034-7046. http://dx.doi.org/10.1128/JVI.00118-08.
58. Mothes W, Sherer NM, Jin J, Zhong P. 2010. Virus cell-to-cell transmission. J. Virol. 84:8360-8368. http://dx.doi.org/10.1128/JVI.00443-10.
59. Sherer NM, Jin J, Mothes W. Directional spread of surface-associated retroviruses regulated by differential virus-cell interactions. J. Virol. 84: 3248-3258. http://dx.doi.org/10.1128/JVI.02155-09.
60. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W. 2007. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat. Cell Biol. 9:310-315. http://dx.doi.org/10.1038/ncb1544.
61. Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ. 2013. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. U. S. A. 110:13109-13113. http://dx.doi.org/10.1073/pnas.1221899110.
62. Dreux M, Garaigorta U, Boyd B, Decembre E, Chung J, Whitten-Bauer C, Wieland S, Chisari FV. 2012. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12:558-570. http://dx.doi.org/10.1016/j.chom.2012.08.010.
63. Pan Q, Ramakrishnaiah V, Henry S, Fouraschen S, de Ruiter PE, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ. 2012. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 61:1330-1339. http://dx.doi.org/10.1136/gutjnl-2011-300449.
64. Tamai K, Shiina M, Tanaka N, Nakano T, Yamamoto A, Kondo Y, Kakazu E, Inoue J, Fukushima K, Sano K, Ueno Y, Shimosegawa T, Sugamura K. 2012. Regulation of hepatitis C virus secretion by the Hrsdependent exosomal pathway. Virology 422:377-385. http://dx.doi.org/10.1016/j.virol.2011.11.009.